Cardiologists across the country have been very busy recently. They are undergoing interventional surgery every day. Every day, patients who need to remove pacemakers and change gene therapy plans are admitted to the hospital, and patients who have been treated are discharged.

Although the cardiology department is busy and is consumed in large quantities every day, for Chen Chang'an, or for Tiantan Biology, this not only does not cause much burden on production, but it is something they are happy to see!

Originally, Chen Changan's plan was to produce 200,000 units per month, which should be able to supply the needs of domestic patients, but he didn't expect that the patients were so enthusiastic!

Two hundred thousand pieces are not enough for a week’s dosage!

But this is not a big problem at all. Tiantan Biological's production capacity is very large. Their company can produce more than 10 million vaccines in a month!

The reason why Chen Changan did not let go of his pace to produce for Ruikang was that they did not have the ability to increase production capacity!

After receiving the instructions from the Food and Drug Administration that the inventory of the drug administration was in urgent need of the supply, Chen Changan immediately added an OEM order of one million gene agents to Tiantan Biology, and asked for subsequent production to speed up the pace. He required at least 400,000 genetic agents to be produced in a week to meet the demand of hospitals in various places.

Each hospital can only perform gene therapy surgery on more than 100,000 patients in a week. If there are more, it will be overloaded and the doctors involved will not be able to bear it.

Anyway, this is not an emergency disease. It is an operation that can be performed at an optional time. There is no need to accumulate all of them in a short time. It is appropriate to split it properly.

After treating more than 100,000 patients a week, the surgery was already very tight, and the doctors in the major hospitals were so busy that they were not stuck.

However, this busy period will not continue. It will only take more than a month. The number of patients receiving gene therapy in various hospitals has gradually decreased, returning to normal standards, with one or two patients a day.

Because there are only 400,000 or 500,000 patients across the country choose to receive gene therapy as soon as possible, accounting for about 5% of the total number of patients. Most of the remaining 90% are ordinary patients. The pacemakers that have been implanted have not expired. There is no rush to try new gene therapy plans.

Only those rich people and patients who cannot afford to install a three-chamber pacemaker due to financial constraints chose to receive gene therapy as soon as possible. It would be quite good if they could have a 5% ratio, far exceeding Chen Changan's estimate.

He originally estimated that it would be considered very successful to have 2% of patients receiving a new treatment plan in the first month, but he didn't expect that the number would double more than double in the end!

When Shang Ning was excitedly reporting sales results to Chen Changan with a stack of financial statements, he was still confused.

"Mr. Chen, in the past month, we have sold nearly one million genetic drugs in total, curing nearly 500,000 patients with pacing disorders!"

"These million genetic agents have created a total of RMB 19 billion in profits for the company!"

This is the biggest money Chen Changan has made since taking over Ruikang!

RMB 19 billion, which is nearly US$3 billion, is already a very large amount of funds!

Even it has become famous all over the world, exporting artificial hematopoietic equipment to dozens of countries. So far, it has only earned more than 10 billion yuan for Ruikang Medical!

And genetic medicines only sold for one month and made a profit of nearly 20 billion yuan!

And more importantly, this is not the final sales of genetic agents, it is even just the beginning!

In the next ten years, nearly 10 million pacemaker implanted patients in China will be treated with genetic drugs one after another.

In other words, Ruikang Medical's genetic medicines are only in China, and there is a market of over 10 billion US dollars waiting to be harvested!

Of course, that's it, but the accounts cannot be settled in this way.

He is now setting at this price, which follows market rules.

The main reason is to leave a way out for domestic pacemaker manufacturers, because half of patients with pacemaker disorders only need to use a single-chamber pacemaker to effectively treat it.

Compared with the surgical fee of 40,000 to 50,000 yuan for genetic medicines, it only costs 10,000 or 20,000 yuan to install a single-chamber pacemaker. There are still some in the market. Many patients with financial difficulties will continue to choose a single-chamber pacemaker.

Most domestic pacemaker companies make single-chamber and double-chamber pacemakers, while only single-chamber pacemakers can be sold. Double-chamber ones are basically using imported products.

However, the imported double-chamber pacemaker has a surgical cost of 10,000 yuan more than genetic medicine treatment. Compared with more advanced gene therapy plans, normal people will no longer choose double-chamber pacemakers and more expensive three-chamber pacemakers in the future!

What his pricing really hits is actually the giants of imported pacemakers! It makes them feel like they are stuck in their throats!

The cost of surgery of 40,000 to 50,000 is exactly 10,000 or 20,000 yuan is cheaper than the cost of implanting imported double-chamber pacemakers, which directly destroyed the market for imported double-chamber pacemakers and three-chamber pacemakers!

Even if these imported pacemaker giants reduce the price of double-chamber pacemakers to similar prices as those of genetic medicine treatment, patients will still choose advanced gene therapy!

And if they can reduce the price of a double-chamber pacemaker to about the same price as that of a single-chamber pacemaker, then there is no need to make money, just go to the Shantang!

This is the point where Chen Changan’s exquisite pricing is focused on the big and let go of the small!

Leave the less profitable single-chamber pacemaker market to domestic pacemaker companies, giving them a space to continue to survive and not react too fiercely.

Chen Changan is still under the banner of contributing to the development of the domestic medical device industry. How can he squeeze the living space of domestic pacemaker companies with his backhand? Isn’t this a slap in the face?

Moreover, even if Chen Changan lowered the price of genetic medicine to about 20,000 yuan to seize the market for single-chamber pacemakers, the profit he could make was actually not much different from now.

Because the selling price is reduced, the profit of single products is naturally lower. In fact, it cannot increase much sales and net profit. Instead, it offended all the domestic pacemaker companies, which is not necessary!

His main goal is to target the markets of international medical giants such as Medtronic, and to grab all their pacemaker markets back, which is what he wants to achieve!

But at present, the effect is very good!

It has only been a month since the genetic agent was launched. The sales of dual-chamber pacemakers and three-chamber pacemakers and defibrillation pacemakers under major pacemaker giants such as Medtronic, St. Jude, and Baiduoli have all seen a sharp decline in sales!

Originally, the three major pacemaker giants could sell about 100,000 high-end pacemakers in China in January. As a result, in October, the three giants sold only less than 1,000 high-end pacemakers in the Chinese market in October!

Their pacemakers' monopoly domination in the Chinese market for decades was completely broken by Ruikang Medical's genetic agents!

However, just as they were anxious and anxiously thinking about how to reverse the bad situation, Chen Changan was already considering how to counterattack the foreign market.

Guan Kou, who was sent by Chen Changan to coordinate the approval of genetic agents in foreign markets, held a stack of documents and reported to him with some concern: "Mr. Chen, the approval of genetic agents in the United States, the European Union, Russia, Southeast Asia and other countries has applied to the health and medical management departments of various countries. If everything goes well, it may be approved within half a year. Of course, the possibility of approval being blocked is not ruled out."

"After all, this kind of medical method that involves cell re-editing and modifying the cell genome has been highly opposed in developed Western countries in recent years, and it may be difficult to pass the approval."

Chen Changan looked at Guan Kou with a worried face and said with a smile on his lips: "Don't worry, the mountain man has his own tricks!"

"No one knows these democrats who are full of freedom and human rights better than me. It is actually very simple to shut up."
Chapter completed!